Her er elevenes dom over den splitter nye skolen Elevene på Garnes ungdomsskule fikk en sniktitt på innsiden.

- Vi har gledet oss til å vise dette! «Joy to the World» var den sjølsagte avslutningssangen torsdag kveld i Bjørnsonhuset. Og den delen av verden som var til stede da elevene ved Molde vgs hadde sin tradisjonelle julekonsert ble virkelig gledet på alle måter, det må slåes fast.

Økt parfymebruk: – Det går utover skolehverdagen På Romsdal videregående skole har elevene blitt oppfordret til å ikke spraye seg med parfyme i klasserommene.

Séminaire réussi sur les veaux organisé par Dairy Japan ! L'événement a mis en lumière les meilleures pratiques pour l'élevage et la santé des veaux. Des experts ont partagé leurs connaissances pour améliorer la production laitière. 🐄🥛 #DairyJapan #Elev... Link

Concentra Biosciences Acquires Elevation Oncology for $0.36 Plus CVR: Board Unanimously Approves July Closing Unanimous board approval for Concentra's acquisition of Elevation Oncology. Deal includes cash payment plus CVR tied to net cash and asset sales. See complete terms.

#ELEV Elevation Oncology Enters into Agreement to Be Acquired by Concentra Biosciences for $0.36 in Cash per Share Plus a Contingent Value Right

www.stocktitan.net/news/ELEV/elevation-onco...

Elevation Oncology Advances Novel HER3 ADC Program While Securing Cash Runway Through 2026 New preclinical data reveals promising HER3 ADC development amid strategic restructuring. Discover key financial metrics and extended cash runway details.

#ELEV Elevation Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates

www.stocktitan.net/news/ELEV/elevation-onco...

Breakthrough Cancer Drug EO-1022 Outperforms Existing HER3 Therapies in Stability and Anti-Tumor Activity New preclinical data reveals EO-1022's enhanced stability and potent anti-tumor effects across multiple cancers. See how this HER3 ADC could transform treatment outcomes.

#ELEV Elevation Oncology Presents Preclinical Proof-of-Concept Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025

www.stocktitan.net/news/ELEV/elevation-onco...

Ungdom drømmer om bybane og laserspill: –Det er jo ingenting for oss i Arna Denne uken fikk de muligheten til å legge frem sine ønsker for utbyggingen av Storaneset.

BREAKING NEWS: ( NASDAQ: #ELEV ) Elevation Oncology to Discontinue Development of EO-3021; Advancing EO-1022, While Evaluating Strategic Options

Elevation Oncology to Discontinue Development of EO-3021; Advancing EO-1022, While Evaluating Strategic Options Elevation Oncology (NASDAQ: ELEV) announced the discontinuation of EO-3021, its Claudin 18.2 antibody-drug conjugate (ADC) for gastric and gastroesophageal junction cancers, following Phase 1 trial results showing a 22.2% objective response rate, deemed insufficient for competitive positioning.The company will focus on advancing EO-1022, a HER3 ADC for HER3-expressing solid tumors, with plans to present preclinical data at AACR Annual Meeting 2025 and file an IND in 2026. A significant restructuring includes a 70% workforce reduction, with estimated costs of $3 million.The company's Chief Medical Officer will step down effective March 31, 2025. With $93.2 million in cash and equivalents as of December 31, 2024, Elevation expects to fund operations into second half of 2026 while evaluating strategic options to maximize shareholder value.

#ELEV Elevation Oncology to Discontinue Development of EO-3021; Advancing EO-1022, While Evaluating Strategic Options

www.stocktitan.net/news/ELEV/elevation-onco...

Quais faltam? (N liguem que tem impostores aí)

#monster #baly #elev

Can Elevation Oncology's $93M War Chest Transform Cancer Treatment? Key Pipeline Updates Strong financial position fuels advancement of Claudin 18.2 ADC therapy and new HER3 candidate. Clinical data expected Q4 2025. Cash runway extends into 2026.

#ELEV Elevation Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Achievements

www.stocktitan.net/news/ELEV/elevation-onco...

Elevation Oncology's Cancer Drug Shows 42.8% Response Rate in Phase 1 Trial, Expands Testing Elevation Oncology advances gastric cancer treatment with promising EO-3021 trial results, initiates combination therapy testing with ramucirumab and dostarlimab. Cash runway extends to 2026.

#ELEV Elevation Oncology Provides Updates on Differentiated ADC Programs and Upcoming Milestones

www.stocktitan.net/news/ELEV/elevation-onco...

Elevation Oncology Unveils Promising HER3 ADC Candidate for Multiple Cancer Types Elevation Oncology advances cancer treatment with new HER3 ADC candidate EO-1022, leveraging proven antibody tech and Synaffix platform for breast, lung, and pancreatic cancers.

#ELEV #LZAGY Elevation Oncology Expands Pipeline with Nomination of EO-1022, a HER3 ADC for the Treatment of HER3-expressing Solid Tumors

#investing #news #StockMarket

www.stocktitan.net/news/ELEV/elevation-onco...

BREAKING NEWS: ( NASDAQ: #ELEV ) Elevation Oncology Presents Preclinical Proof-of-Concept Data Supporting Combination Potential of EO-3021 with VEGFR2 or PD-1 Inhibitors at ESMO Immuno-Oncology Annual Congress 2024

#StockMarket #News

News; ( NASDAQ: #ELEV ) Elevation Oncology to Present at the Piper Sandler 36th Annual Healthcare Conference

#StockMarket #News

#ELEV Elevation Oncology to Present at the Piper Sandler 36th Annual Healthcare Conference

www.stocktitan.net/news/ELEV/elevation-onco...

BREAKING NEWS: ( NASDAQ: #ELEV ) August Wrap-up; New Stocks in biotech, transportation, tech, mining and defense

#StockMarket #News

Ansatt ved barneskole siktet for #voldtekt av #elev, nyhetsvarsel Ansatt ved barneskole siktet for voldtekt av elev www.aesby.no/nyheter/i/wgeQwA/ansatt-...